iPS Research

Currently, the field of iPS cells is subject of intensive research. With regard to their later therapeutic application, the advantage of iPS cells is that their generation does not require the destruction of embryos and that they are often immunologically more compatible than human embryonic stem cells.

The process of reprogramming which genetically ‘resets’ cells can cause the occurrence of short- as well as long-term genetic anomalies in iPS cells. These anomalies can, amongst other things, facilitate tumour growth. Therefore, researchers currently investigate how the process of reprogramming can be altered in order to decrease genetic changes. Additionally, standardised procedures for quality control of iPS cells are being developed.

A further aspect of iPS research consists in improving the efficiency of iPS cell derivation. The procedures applied at present only succeed in reprogramming a small number of somatic cells. However, large numbers of iPS cells are necessary to use them therapeutically. Additionally, hES research as well as iPS research focus on improving the cultivation and safeguarding a targeted as well as homogenous differentiation of stem cells. Furthermore, gaps in knowledge with regard to both stem cell types remain concerning the targeted suppression of cell division of stem cells in vivo that are either undifferentiated or not suitably differentiated.

Besides, stem cell research is targeted at gaining a fundamental understanding of early embryogenesis. Current research thus also attempts to explore the differences between hES cells, iPS cells, adult stem cells and SCNT cells.

Further information on the current state of research:

Dobrzyński, Maciej / Rybak, Zbigniew / Szymonowicz, Maria / Zakrzewski, Wojciech (2019): Stem cells: past, present, and future. In: Stem Cell Research and Therapy 10, no pag. doi: 10.1186/s13287-019-1165-5 Online Version 

Almeida Santos, João M. / Braganca, José / Lopes, João A. / Mendes-Silva, Leonardo (2019): Induced pluripotent stem cells, a giant leap for mankind therapeutic applications. In: World Journal of Stem Cells 11(7), 421–430. doi: 10.4252/wjsc.v11.i7.421 Online Version 

Attwood, Stephen W. / Edel, Michael J. (2019): iPS Cell Technology and the Problem of Genetic Instability – Can it Ever Be Safe for Clinical Use? In: Journal of Clinical Medicine 8(3). doi: 10.3390/jcm8030288 Online Version 

Hu, Jing / Wang, Jimei (2019): From embryonic stem cells to induced pluripotent stem cells – Ready for clinical therapy? In: Clinical Transplantation. The Journal of Clinical and Translational Research 33(6). doi: 10.1111/ctr.13573 Online Version 

Wird geladen